June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
OCT ANGIOGRAPHY of type 1 neovascularization in amd WITH LONG-TERM FOLLOW UP ANALYSIS
Author Affiliations & Notes
  • Juan Pablo Davila
    MEDICAL RETINA, JULES STEIN EYE INSTITUTE, Los Angeles, California, United States
  • David Sarraf
    MEDICAL RETINA, JULES STEIN EYE INSTITUTE, Los Angeles, California, United States
  • Mansour Rahimi
    MEDICAL RETINA, JULES STEIN EYE INSTITUTE, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Juan Pablo Davila, None; David Sarraf, ALLERGAN (C), BAYER (C), GENETECH (C), NOVARTIS (C), OPTOVUE (C), REGENERON (C); Mansour Rahimi, None
  • Footnotes
    Support  NONE
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 400. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Juan Pablo Davila, David Sarraf, Mansour Rahimi; OCT ANGIOGRAPHY of type 1 neovascularization in amd WITH LONG-TERM FOLLOW UP ANALYSIS. Invest. Ophthalmol. Vis. Sci. 2017;58(8):400.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To describe the optical coherence tomography angiography (OCTA) analysis of type 1 choroidal neovascularization (CNV) in age related macular degeneration (AMD) after at least one year of treatment with anti-vascular endothelial growth factor (VEGF) injection therapy.

Methods : This retrospective OCTA analysis recruited eyes with type 1 neovascularization and AMD that underwent baseline and follow up OCTA imaging for at least 1 year. The findings of qualitative and quantitative OCTA analysis were reviewed at baseline and at last follow up. Various microvascular morphological features of the type 1 lesion were studied and a measurement of the area and density of the type 1 lesion was performed and the findings between the baseline and follow up visits were compared.

Results : Thirty one eyes (13 right and 18 left eyes) with complete one year follow up OCT-A scans were reviewed. Fifteen male and 16 female patients, mean age 83.52 years (66-97 years).
Mean visual acuity (VA) at month 0 was 0.51 LogMAR (20/64 Snellen). Previous anti-VEGF treatment, 6.3 aflibercept injections (24 eyes) and 13.64 ranibizumab injections (14 eyes).
Mean area of type 1 CNV at baseline was 5.384mm2 (0.2829-35.75mm2) compared to 5.921mm2 (0.381-35.76mm2) at 12 months. We observe increase of the CNV area in 22 eyes (p<0.001 / SD 1.128), mean increase area 1.315mm2. Nine patients had decreased of the CNV area after one year (p=0.0426 / SD 2.083), mean decrease area -1.363mm2. Mean VA had no change 0.48LogMAR (20/60 Snellen). The average treatment during the one year follow up was 3.46 aflibercept and 1.5 ranibizumab injections respectively.

Conclusions : Quantitative analyses can be performed using OCT-A to follow the progression of type-1 choroidal membranes. Despite the anti-VEGF therapy type-1 CNV in AMD tend to increase in area throughout time even though visual acuity remains stable.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×